Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Drugmakers including...

    Drugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement list

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-29T09:15:39+05:30  |  Updated On 2021-08-16T11:11:14+05:30

    Seventy new drugs such as Roche's breast cancer treatment Pertuzumab, sold under the trade name Perjeta, Novartis's dermatitis treatment Omalizumab, branded as Xolair, will be added to the list, the National Healthcare Security Administration said on its website on Thursday.


    New Delhi: Drugmakers including Roche and Novartis' have agreed to cut the prices of some of their newest drugs by an average of 61% in China in order to get on a national reimbursement scheme list, regulators said.


    Addition to the list is likely to boost sales volume by opening up markets in smaller and less-affluent Chinese cities, but some industry insiders have cautioned that only offering deep price cuts in China could spark criticism of the drugmakers in other markets.


    Seventy new drugs such as Roche's breast cancer treatment Pertuzumab, sold under the trade name Perjeta, Novartis's dermatitis treatment Omalizumab, branded as Xolair, will be added to the list, the National Healthcare Security Administration said on its website on Thursday.


    Chinese patients are allowed to use their state medical insurance to cover a significant portion of the cost of drugs named on the list.


    Almost all the imported drugs added to the list in the latest update had the "lowest prices globally", the NHSA said in its statement.


    "China is and will be the ultimate high-volume, low-price market, and so international companies feel that they'll have to take a big pay cut but make up for the volume," Brad Loncar, chief executive of biopharma sector-dedicated Loncar Investments, told Reuters.


    Tumour and diabetes medicines saw an average price cut of about 65%, according to the NHSA.


    Other drugs added included Adalimumab, an arthritis treatment which AbbVie sells as Humira, one the top-selling drugs in the world.


    Also included was cancer treatment Tyvyt, or Sintilimab, co-developed by Chinese drugmaker Innovent Biologics and Eli Lilly. It is considered to be a PD-1/PD-L1 treatment, a category of novel drugs that work on the immune system to fight cancer cells.


    China has already approved five PD-1/PD-L1 treatments, including two top-selling global blockbusters made by foreign firms Bristol-Myers Squibb and Merck. However neither have been added to the list.


    Analysts say domestically developed Tyvyt's early inclusion could give it an advantage over its foreign rivals.


    "Maybe (Chinese PD-1/PD-L1 products) don't come in and compete on day one with international (pharmas) in all indications, but just getting a foot in the door might already be a big step for them," UBS analyst Michael Leuchten told Reuters before the NHSA announcement.


    By Roxanne Liu and Brenda Goh

    Read Also: Pfizer, Novartis lead USD 2 billion spending spree on gene therapy production
    breast cancer china chinese drugmakers drug price Drugmakers Eli Lilly Healthcare Humira Innovent Biologics Novartis omalizumab pertuzumab reimbursement scheme list Roche Xolair 
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      Hydroxychloroquine not approved as anti-malarial drug in India, says Ipca Laboratories Joint MD

      Hydroxychloroquine not approved as anti-malarial drug in India, says Ipca Laboratories Joint MD

      Wellthy Therapeutics announces Rs 30 crore financing round led by Saama Capital

      Wellthy Therapeutics announces Rs 30 crore financing round led by Saama Capital

      Lasa Supergenerics gets FDA nod for Progesterone

      Lasa Supergenerics gets FDA nod for Progesterone

      SMS Pharma updates against USFDA statement on Ranitidine

      SMS Pharma updates against USFDA statement on Ranitidine

      Lupin Contributes Rs 21 crores in battle against COVID-19

      Lupin Contributes Rs 21 crores in battle against COVID-19

      AstraZeneca gets USFDA nod for Koselugo for paediatric patients with neurofibromatosis type 1

      AstraZeneca gets USFDA nod for Koselugo for paediatric patients with neurofibromatosis type 1

      KKRs Envision Healthcare hires bank to explore debt restructuring: Report

      KKR's Envision Healthcare hires bank to explore debt restructuring: Report

      Pfizer clinches coronavirus vaccine deal with German drugmaker, sees potential in antiviral treatment

      Pfizer clinches coronavirus vaccine deal with German drugmaker, sees potential in antiviral...

      Bioheaven gets USFDA go ahead to begin phase 2 trial of intranasal vazegepant to treat lung inflammation after COVID-19 infection

      Bioheaven gets USFDA go ahead to begin phase 2 trial of intranasal vazegepant to treat lung...

      GSK , Vir Biotechnology enter collaboration to find coronavirus solutions

      GSK , Vir Biotechnology enter collaboration to find coronavirus solutions

      India should become self-reliant in medical equipment, devices: Kasturirangan

      India should become self-reliant in medical equipment, devices: Kasturirangan

      Cancer tech Patent Infringment: Gilead Sciences told to pay 1.2 billion dollars to Bristol-Myers Squibb

      Cancer tech Patent Infringment: Gilead Sciences told to pay 1.2 billion dollars to Bristol-Myers...

      Popular Stories

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs...

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Johnson n Johnson ties up with CSIR-IMTECH to Develop Innovative Tuberculosis Treatments

      Johnson n Johnson ties up with CSIR-IMTECH to Develop Innovative Tuberculosis Treatments

      Bring Cataract Lenses, Syringes, IV Fluid Sets, Urine Bags under Price Ceiling: Maha Govt tells Health Ministry

      Bring Cataract Lenses, Syringes, IV Fluid Sets, Urine Bags under Price Ceiling: Maha Govt tells...

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X